Nuwellis, Inc. (NUWE) Latest Company News

Aug 25, 2026, 12:30 UTC
Nuwellis entered into a strategic commercial agreement with Atrility Medical to expand its pediatric and critical care portfolio, with a milestone-based pathway to U.S. distribution.
Source:
- globenewswire.com
Aug 13, 2026, 12:00 UTC
Nuwellis, Inc. reported financial results for the three and six months ended June 30, 2026, highlighting double-digit revenue growth and expanded gross margin.
Source:
- globenewswire.com
Aug 6, 2026, 12:30 UTC
Nuwellis, Inc. announced the appointment of Dale Brady as Principal R&D Engineer on August 6, 2026.
Source:
- globenewswire.com
Aug 4, 2026, 12:30 UTC
Nuwellis announced a strategy to develop next-generation Aquadex platform capabilities for future critical care applications including immunomodulation and extracorporeal blood purification.
Source:
- globenewswire.com
Jul 31, 2026, 12:39 UTC
NUWELLIS announced the completion of a registered direct offering priced at market, raising $3.4 million, under Nasdaq rules.
Source:
Jul 31, 2026, 12:39 UTC
Nuwellis received $3.1 million from the exercise of previously issued warrants from the June 2026 public offering.
Source:
- globenewswire.com
Jul 16, 2026, 12:30 UTC
Nuwellis was awarded a U.S. patent for a novel catheter technology designed to enhance extracorporeal therapies.
Source:
- globenewswire.com
Jun 25, 2026, 12:30 UTC
Nuwellis, Inc. installed three Aquadex SmartFlow systems at a pediatric healthcare provider in Michigan, marking its first pediatric program in the state.
Source:
- globenewswire.com
- globenewswire.com
Jun 18, 2026, 00:00 UTC
John L. Erb resigned as Chief Executive Officer of Nuwellis, Inc., effective June 30, 2026, and Michael McCormick was appointed as his successor.
Jun 10, 2026, 12:30 UTC
Nuwellis expanded its collaboration with a major South Carolina healthcare system by installing new Aquadex SmartFlow devices at one of its children's hospitals and upgrading devices at two existing locations.
Source:
- globenewswire.com
Jun 9, 2026, 01:46 UTC
Nuwellis, Inc. closed a registered public offering of common stock and warrants, raising approximately $6.0 million in gross proceeds.
Source:
Jun 5, 2026, 12:30 UTC
Nuwellis, Inc. priced a public offering of 20,000,000 shares of common stock (or pre-funded warrants) with accompanying warrants for gross proceeds of approximately $6 million.
Source:
- globenewswire.com

NUWE

Nuwellis entered into a strategic commercial agreement with Atrility Medical to expand its pediatric and critical care portfolio, with a milestone-based pathway to U.S. distribution.

Nuwellis, Inc. reported financial results for the three and six months ended June 30, 2026, highlighting double-digit revenue growth and expanded gross margin.

Nuwellis, Inc. announced the appointment of Dale Brady as Principal R&D Engineer on August 6, 2026.

Nuwellis announced a strategy to develop next-generation Aquadex platform capabilities for future critical care applications including immunomodulation and extracorporeal blood purification.

NUWELLIS announced the completion of a registered direct offering priced at market, raising $3.4 million, under Nasdaq rules.

Nuwellis received $3.1 million from the exercise of previously issued warrants from the June 2026 public offering.

Nuwellis was awarded a U.S. patent for a novel catheter technology designed to enhance extracorporeal therapies.

Nuwellis, Inc. installed three Aquadex SmartFlow systems at a pediatric healthcare provider in Michigan, marking its first pediatric program in the state.

John L. Erb resigned as Chief Executive Officer of Nuwellis, Inc., effective June 30, 2026, and Michael McCormick was appointed as his successor.

Nuwellis expanded its collaboration with a major South Carolina healthcare system by installing new Aquadex SmartFlow devices at one of its children's hospitals and upgrading devices at two existing locations.

Nuwellis, Inc. closed a registered public offering of common stock and warrants, raising approximately $6.0 million in gross proceeds.

Nuwellis, Inc. priced a public offering of 20,000,000 shares of common stock (or pre-funded warrants) with accompanying warrants for gross proceeds of approximately $6 million.